Aurinia Selects Worldwide for Phase III Lupus Trial

Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study.

Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study, a Phase III clinical trial for the treatment of active lupus nephritis.

Read the full release here